These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29594879)

  • 1. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.
    Magnusson SE; Altenburg AF; Bengtsson KL; Bosman F; de Vries RD; Rimmelzwaan GF; Stertman L
    Immunol Res; 2018 Apr; 66(2):224-233. PubMed ID: 29594879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
    Altenburg AF; Magnusson SE; Bosman F; Stertman L; de Vries RD; Rimmelzwaan GF
    Clin Exp Immunol; 2017 Oct; 190(1):19-28. PubMed ID: 28665497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
    Meseda CA; Atukorale V; Soto J; Eichelberger MC; Gao J; Wang W; Weiss CD; Weir JP
    Sci Rep; 2018 Mar; 8(1):5364. PubMed ID: 29599502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice.
    Magnusson SE; Reimer JM; Karlsson KH; Lilja L; Bengtsson KL; Stertman L
    Vaccine; 2013 Mar; 31(13):1725-33. PubMed ID: 23384754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
    Hessel A; Schwendinger M; Fritz D; Coulibaly S; Holzer GW; Sabarth N; Kistner O; Wodal W; Kerschbaum A; Savidis-Dacho H; Crowe BA; Kreil TR; Barrett PN; Falkner FG
    PLoS One; 2010 Aug; 5(8):e12217. PubMed ID: 20808939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.
    Di Mario G; Soprana E; Gubinelli F; Panigada M; Facchini M; Fabiani C; Garulli B; Basileo M; Cassone A; Siccardi A; Donatelli I; Castrucci MR
    Pathog Glob Health; 2017 Mar; 111(2):69-75. PubMed ID: 28081672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
    Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
    Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.
    Chavan R; Marfatia KA; An IC; Garber DA; Feinberg MB
    J Virol; 2006 Aug; 80(15):7676-87. PubMed ID: 16840346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.
    Cox F; Saeland E; Baart M; Koldijk M; Tolboom J; Dekking L; Koudstaal W; Lövgren Bengtsson K; Goudsmit J; Radošević K
    Virol J; 2015 Dec; 12():210. PubMed ID: 26643820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
    Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.
    Altenburg AF; van Trierum SE; de Bruin E; de Meulder D; van de Sandt CE; van der Klis FRM; Fouchier RAM; Koopmans MPG; Rimmelzwaan GF; de Vries RD
    Sci Rep; 2018 Apr; 8(1):6474. PubMed ID: 29692427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.
    Di Mario G; Sciaraffia E; Facchini M; Gubinelli F; Soprana E; Panigada M; Bernasconi V; Garulli B; Siccardi A; Donatelli I; Castrucci MR
    Pathog Glob Health; 2017 Mar; 111(2):76-82. PubMed ID: 28079473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.
    Smith G; Liu Y; Flyer D; Massare MJ; Zhou B; Patel N; Ellingsworth L; Lewis M; Cummings JF; Glenn G
    Vaccine; 2017 Sep; 35(40):5366-5372. PubMed ID: 28844407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.